Dataset Information


Chronic SSRI treatment exacerbates serotonin deficiency in humanized Tph2 mutant mice.

ABSTRACT: Selective serotonin reuptake inhibitors (SSRIs) are a major class of antidepressants that act by blocking inward transport of serotonin (5-HT) into presynaptic neurons mediated by the serotonin transporter (SERT). Both reuptake and ongoing synthesis are essential in supporting intraneuronal serotonin concentrations in serotonergic neurons. A rare mutation in tryptophan hydroxylase 2 (Tph2), the rate limiting enzyme for 5-HT synthesis, was identified in several patients with major depression, and knock-in mice expressing the analogous mutation (R439H Tph2 KI) show 80% reduction in 5-HT synthesis and tissue levels. Chronic treatment with SSRIs (fluoxetine and paroxetine) resulted in a dramatic further depletion of 5-HT tissue levels in R439H Tph2 KI mice (down to 1-3% of wild type levels) while having little effects in wild-type controls. Treatment with the 5-HT precursor 5-hydroxytryptophan (5-HTP) restored 5-HT tissue content in mutant mice, and cotreatment with 5-HTP and fluoxetine essentially prevented the depleting effect of a chronic SSRI. These data demonstrate that chronic SSRI treatment could further exacerbate the 5-HT deficiency in Tph2 mutation carriers, and this can be prevented by 5-HTP supplementation.


PROVIDER: S-EPMC3547473 | BioStudies | 2013-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6650329 | BioStudies
2019-01-01 | S-EPMC6898594 | BioStudies
2019-01-01 | S-EPMC6444596 | BioStudies
2017-01-01 | S-EPMC5561191 | BioStudies
2018-03-07 | GSE111491 | GEO
2010-01-01 | S-EPMC2927054 | BioStudies
1000-01-01 | S-EPMC4946063 | BioStudies
2015-01-01 | S-EPMC4624493 | BioStudies
2013-01-01 | S-EPMC3812685 | BioStudies
2016-01-01 | S-EPMC4939133 | BioStudies